---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-084498"
form_type: "8-K"
ticker: "CERO"
cik: "0001870404"
company_name: "CERO THERAPEUTICS HOLDINGS, INC."
filed_at: "2025-09-04T23:59:59+00:00"
generated_at: "2026-05-17T08:21:42.704918+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# CERo Therapeutics receives Nasdaq delisting notice for equity shortfall, appeals

## Summary
- Nasdaq staff determined company fails minimum $2.5M stockholders' equity requirement for continued listing.
- Trading suspension and delisting scheduled for September 8, 2025, unless hearing stays action.
- Company requested hearing on September 3, 2025, to appeal determination and present compliance plan.
- Plan may include public or private financing to increase equity; no assurance of success.
- Company subject to mandatory hearings panel monitor until May 7, 2026, after prior non-compliance.

## SEC filing metadata
- accession: 0001213900-25-084498
- form_type: 8-K
- ticker: CERO
- cik: 0001870404
- company_name: CERO THERAPEUTICS HOLDINGS, INC.
- filed_at: 2025-09-04T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1870404/000121390025084498/0001213900-25-084498-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1870404/000121390025084498/ea0255967-8k_cero.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-084498
- JSON: https://secwatch.observer/filing/0001213900-25-084498.json
- Plain text: https://secwatch.observer/filing/0001213900-25-084498.txt

## Key facts
- Listing & Compliance Notices
  CERO THERAPEUTICS HOLDINGS, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b), 5815(d)(4)(B)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: stockholders equity
  - Rules: 5550(b), 5815(d)(4)(B)
  source text: August 28, 2025, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “ Company ”), received a letter from the staff at the Nasdaq Listing Qualifications department notifying the Company that such staff had determined that the Company does not comply with the minimum stockholders’ equity requirement of $2,500,000 (the “ Stockholders’ Equity Requirement ”) for continued listing on the Nasdaq Capital Market (“ Nasdaq ”) set forth in Nasdaq Rule 5550(b). As previously disclosed, the Company previously had been out of compliance with Nasdaq continued listing requirements until, on May 7
  evidence_url: https://www.sec.gov/Archives/edgar/data/1870404/000121390025084498/0001213900-25-084498-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.